-
Business
-

Boots to Prescribe Medical Cannabis in High Street First

By
Distilled Post Editorial Team

The blue and white frontage of a Boots store is among the most familiar sights on the British high street, a place where generations have collected NHS prescriptions and asked a pharmacist about a cough that would not shift. This month the brand has attached its name to something different. SureLeaf, a private online service from Boots Online Doctor, will assess adults aged 25 and over for a medical cannabis prescription where chronic pain has resisted conventional treatment, and also for generalised anxiety disorder or insomnia. Boots says assessment, treatment and ongoing care are consultant-led. The signal it sends is difficult to ignore. A product category that spent years at the margins of British medicine now carries the livery of the country's most recognisable retailer.

Parliament legalised medical cannabis in November 2018, after a boy from Northern Ireland whose epilepsy medicine had been confiscated at the border became the public face of a cause ministers could not resist. The law changed quickly and practice did not. NHS prescribing remains confined largely to rare severe forms of epilepsy and to spasticity in multiple sclerosis, with nausea caused by chemotherapy the other recognised use. National guidance concluded that the evidence for wider use did not justify NHS funding. Patients whose conditions fall outside those categories were left with one route, which was to pay, and a sizeable private clinic sector grew to meet them. Boots has not created that market. It has joined it, and in doing so has changed how it looks.

The question for the NHS is what follows when its own gate stays shut while a trusted brand opens another. Legitimacy is moving faster than evidence. A familiar name reassures patients, and reassurance is not data. A major review published this year pooled 54 randomised trials across mental health and substance use disorders and found no significant benefit for anxiety or post-traumatic stress disorder, and none for psychotic disorders. The insomnia evidence came from four trials, was inconsistent and was rated low in quality. Tic disorders such as Tourette syndrome did respond, but only to combined formulations, and some benefit appeared for people trying to reduce their own cannabis use. The authors judged routine prescribing for these conditions rarely justified. Two of the conditions SureLeaf lists sit in the territory where that review found the weakest support.

Two qualifications are needed. The review did not examine chronic pain, the indication on which Boots is concentrating its research, so it neither condemns nor vindicates the service's central offer. The requirement that conventional treatment must already have failed is also a sensible one, because it keeps the service away from first-line use. Industry bodies and patient groups argue, with some force, that trials struggle to capture what clinicians see in practice and that patient-reported outcomes deserve weight. That argument applies to many treatments before their evidence matures, and it carries most credibility when it comes with a plan to generate better data.

The research partnership with the University of Nottingham may prove the most significant element of the launch. Boots says it will examine patient outcomes, prescribing practice and patient experience in chronic pain. If the design is rigorous, with defined outcomes, independent analysis and publication whatever the result, a commercial rollout could produce the real-world evidence that the NHS has never had the means to gather. If it amounts to a register of satisfied customers, it will lend scientific gloss to a retail proposition. The tests are straightforward. Will the findings be published in full, how will patients who stop treatment be counted, and who controls the analysis? Policymakers should be asking these questions now, because results produced inside a company's own service will carry weight in future debates about NICE guidance and commissioning, whatever their quality.

Practical consequences will land on the NHS whether or not it has a role. GPs cannot prescribe these products themselves, since only specialist doctors may do so, but they will see patients who take them. That brings medicines reconciliation and advice on driving, along with requests to record or endorse treatment they did not initiate. Pain services with long waits will watch some patients leave and a few return. Integrated care boards have no visibility of how many of their residents use private cannabis prescriptions, and so no basis for planning. That gap is a data problem as much as a clinical one, in a health service that has spent a decade arguing for a single view of the patient.

Regulators face their own test. Online prescribing of controlled drugs is a model that inspectors continue to scrutinise, and a name as large as Boots raises the stakes of any lapse in standards. Industry will follow the Nottingham work closely as well. Most products reaching British patients are imported unlicensed preparations, and a credible UK evidence base is the only route from there towards licensed products that the NHS could ever consider commissioning.

The NHS did not choose to hand this field to the private sector, but it has left it there all the same, and Boots has made the consequence visible. The cleanest outcome would see evidence generated in the private market feed a proper reassessment of NHS access, so that the question is settled on data. The alternative is a mainstream service resting on thin evidence in a health system with no stake in the result. The brand on the screen will reassure patients long before the research can, and the NHS will be left to deal with whatever follows.